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In open trials, 1-Hz repetitive Transcranial Magnetic Stimulation (rTMS) to the 
Supplementary Motor Area (SMA) improved symptoms and normalized cortical hyper-
excitability of patients with Obsessive-Compulsive Disorder (OCD). Here we present the 
results of a randomized sham-controlled double-blind study.  
Medication-resistant OCD patients (n=21) were assigned 4 weeks of either active or 
sham rTMS to the SMA bilaterally. rTMS parameters consisted of 1200 pulses/day, at 1-
Hz and 100% of Motor Threshold (MT). Eighteen patients completed the study. 
Response to treatment was defined as a  25% decrease on the Yale-Brown Obsessive 
Compulsive Scale (Y-BOCS). Non-responders to sham and responders to active or sham 
rTMS were offered 4 additional weeks of open active rTMS.  
After 4 weeks, the response rate in the completer sample was 67% (6 out of 9) with 
active and 22% (2 out of 9) with sham rTMS. At 4 weeks, patients receiving active rTMS 
showed on average a 25% reduction in the Y-BOCS compared to a 12% reduction in 
those receiving the sham. In those who received 8 weeks of active rTMS, OCD 
symptoms improved from 28.2±5.8 to 14.5±3.6. In patients randomized to active rTMS, 
MT measures on the right hemisphere increased significantly over time. At the end of 4 
weeks of rTMS the abnormal hemispheric laterality found in the group randomized to 
active rTMS normalized.  
The results of the first randomized sham-controlled trial of SMA stimulation in the 
treatment of resistant OCD support further investigation into the potential therapeutic 
applications of rTMS in this disabling condition.  
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